Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: July 21, 2022
Accepted: November 21, 2022
Published online: February 01, 2023

Number of Print Pages: 10
Number of Figures: 3
Number of Tables: 7

ISSN: 1015-2008 (Print)
eISSN: 1423-0291 (Online)

For additional information: https://www.karger.com/PAT

Abstract

Introduction: The present study aimed to analyze the clinical features and laboratory markers of patients with Delta variant SARS-CoV-2 and explore the role of platelet in predicting the severity of Delta. Methods: This retrospective, observational study was conducted on 863 patients laboratory-confirmed Delta variant SARS-CoV-2. These cases were sub-classified based on disease severity into mild (n = 304), moderate (n = 537), and severe (n = 22). A series of laboratory findings and clinical data were collected and analyzed during hospitalization. Results: Of 863 hospitalized patients with Delta, the median age was 38 years (interquartile range, 30–51 years) and 471 (54.58%) were male. The most common clinical symptoms mainly included cough, fever, pharyngalgia, expectoration, dyspnea, fatigue, and headache, and the commonest comorbidities were hypertension and diabetes. Among the hematological variables, neutrophil count, red blood cell count, and hemoglobin, were found to be statistically significant with regard to subcategories based of disease severity (p < 0.05). Among coagulation parameters, there was a statistically significant difference in D-dimer, fibrinogen, international normalized ratio, and prothrombin time (p < 0.05). Statistically significant differences were observed in platelet markers including platelet count, large platelet count, and plateletcrit (p < 0.05). Additionally, there was strong correlation between platelet and other parameters with disease severity. Logistical regression analysis and ROC curves showed that D-dimer was a single best marker of disease severity (p = 0.005, p < 0.0001); however, platelet (p = 0.009, p = 0.002) and plateletcrit (p = 0.002, p = 0.001) could also predict severe disease. Platelet was identified as an independent risk factor for severe Delta. Conclusion: Low platelet may be a marker of disease severity in Delta variant SARS-CoV-2 and may contribute to determine the severity of patients infected with Delta.

© 2023 S. Karger AG, Basel

References Li M, Lou F, Fan H. SARS-CoV-2 Variants of Concern Delta: a great challenge to prevention and control of COVID-19. Signal Transduct Target Ther. 2021;6(1):349. Galloway SE, Paul P, MacCannell DR, Johansson MA, Brooks JT, MacNeil A, et al. Emergence of SARS-CoV-2 B.1.1.7 lineage: United States, December 29, 2020–January 12, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(3):95–9. Sheikh A, McMenamin J, Taylor B, Robertson C; Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461–2. Torjesen I. Covid-19: Delta variant is now UK’s most dominant strain and spreading through schools. BMJ. 2021;373:n1445. Mellema RA, Crandell J, Petrey AC. Platelet dysregulation in the pathobiology of COVID-19. Hamostaseologie. 2022;42(4):221–8. Zaid Y, Puhm F, Allaeys I, Naya A, Oudghiri M, Khalki L, et al. Platelets can associate with SARS-cov-2 RNA and are hyperactivated in COVID-19. Circ Res. 2020;127(11):1404–18. Zarychanski R, Houston DS. Assessing thrombocytopenia in the intensive care unit: the past, present, and future. Hematology Am Soc Hematol Educ Program. 2017;2017(1):660–6. Violi F, Cammisotto V, Pignatelli P. Thrombosis in Covid-19 and non-Covid-19 pneumonia: role of platelets. Platelets. 2021;32(8):1009–17. Zhang Y, Zeng X, Jiao Y, Li Z, Liu Q, Ye J, et al. Mechanisms involved in the development of thrombocytopenia in patients with COVID-19. Thromb Res. 2020;193:110–5. Wool GD, Miller JL. The impact of COVID-19 disease on platelets and coagulation. Pathobiology. 2021;88(1):15–27. Shen S, Zhang J, Fang Y, Lu S, Wu J, Zheng X, et al. SARS-CoV-2 interacts with platelets and megakaryocytes via ACE2-independent mechanism. J Hematol Oncol. 2021;14(1):72. Manne BK, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben C, et al. Platelet gene expression and function in patients with COVID-19. Blood. 2020;136(11):1317–29. Zhu J, Pang J, Ji P, Zhong Z, Li H, Li B, et al. Coagulation dysfunction is associated with severity of COVID-19: a meta-analysis. J Med Virol. 2021;93(2):962–72. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020;506:145–8. Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost. 2020;18(6):1469–72. Mei H, Luo L, Hu Y. Thrombocytopenia and thrombosis in hospitalized patients with COVID-19. J Hematol Oncol. 2020;13(1):161. El-Khaiat MM, El-Lehlah AM, Kesheita MA, Abdel-Samiee M, Teima AAA. Association between thrombocytopenia and the severity of Covid-19 infection among hospitalized Egyptian patients. Ann Med Surg. 2022;79:103973. Esmaeel HM, Ahmed HA, Elbadry MI, Khalaf AR, Mohammed NA, Mahmoud HA, et al. Coagulation parameters abnormalities and their relation to clinical outcomes in hospitalized and severe COVID-19 patients: prospective study. Sci Rep. 2022;12(1):13155. Wichmann D, Sperhake JP, Lutgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020;173(4):268–77. Rapkiewicz AV, Mai X, Carsons SE, Pittaluga S, Kleiner DE, Berger JS, et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series. EClinicalMedicine. 2020;24:100434. Piva S, Filippini M, Turla F, Cattaneo S, Margola A, De Fulviis S, et al. Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy. J Crit Care. 2020;58:29–33. Loconsole D, Centrone F, Morcavallo C, Campanella S, Sallustio A, Accogli M, et al. Rapid spread of the SARS-CoV-2 variant of concern 202012/01 in southern Italy (December 2020–March 2021). Int J Environ Res Public Health. 2021;18(9):4766. Li S, Jiang L, Li X, Lin F, Wang Y, Li B, et al. Clinical and pathological investigation of patients with severe COVID-19. JCI Insight. 2020;5(12). Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–9. Rolla R, Puricelli C, Bertoni A, Boggio E, Gigliotti CL, Chiocchetti A, et al. Platelets: “multiple choice” effectors in the immune response and their implication in COVID-19 thromboinflammatory process. Int J Lab Hematol. 2021;43(5):895–906. Savla SR, Prabhavalkar KS, Bhatt LK. Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management. Expert Rev Anti Infect Ther. 2021;19(11):1397–413. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020;20(10):1135–40. Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int J Hematol. 2021;113(1):45–57. Pujani M, Raychaudhuri S, Singh M, Kaur H, Agarwal S, Jain M, et al. An analysis of hematological, coagulation and biochemical markers in COVID-19 disease and their association with clinical severity and mortality: an Indian outlook. Am J Blood Res. 2021;11(6):580–91. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. Ozen M, Yilmaz A, Cakmak V, Beyoglu R, Oskay A, Seyit M, et al. D-Dimer as a potential biomarker for disease severity in COVID-19. Am J Emerg Med. 2021;40:55–9. Liu Y, Sun W, Guo Y, Chen L, Zhang L, Zhao S, et al. Association between platelet parameters and mortality in coronavirus disease 2019: retrospective cohort study. Platelets. 2020;31(4):490–6. Rohlfing AK, Rath D, Geisler T, Gawaz M. Platelets and COVID-19. Hamostaseologie. 2021;41(5):379–85. Nigam JS, Kumar A, Sinha R, H H, Kumar N, Surabhi, et al. Association of peripheral blood parameters with outcomes of COVID-19 infection in a tertiary care setting of eastern India: an institute-based study. Cureus. 2021;13(12):e20745. Chen H, Yang G, Long Y, Li C. Lymphocyte and platelet counts, as well as interleukin-6 levels, predict mortality of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2021;2021:5582908. Shang W, Dong J, Ren Y, Tian M, Li W, Hu J, et al. The value of clinical parameters in predicting the severity of COVID-19. J Med Virol. 2020;92(10):2188–92. Xiao LN, Ran X, Zhong YX, Li SS. Clinical value of blood markers to assess the severity of coronavirus disease 2019. BMC Infect Dis. 2021;21(1):921. Zou X, Li S, Fang M, Hu M, Bian Y, Ling J, et al. Acute physiology and chronic Health evaluation II score as a predictor of hospital mortality in patients of coronavirus disease 2019. Crit Care Med. 2020;48(8):e657–65. Article / Publication Details

First-Page Preview

Received: July 21, 2022
Accepted: November 21, 2022
Published online: February 01, 2023

Number of Print Pages: 10
Number of Figures: 3
Number of Tables: 7

ISSN: 1015-2008 (Print)
eISSN: 1423-0291 (Online)

For additional information: https://www.karger.com/PAT